For Pharma & Institutions

Mimicry Suite

Mimicry discovery is slow, and incomplete. You shouldn't need a decade to find the epitope that changes everything.

One platform. Every dimension of mimicry analysis.

BLAST finds sequence similarity. Our suite finds functional mimicry — combining sequence, structure, biochemical properties, and immunological context in a single integrated workflow.

Built for pharmaceutical discovery, academic research, and institutional pipelines. Enterprise-grade compute, validated algorithms, and direct connection to real-world patient outcomes via MAR.

Precision,
at every layer.

Sequence Analysis

Mimicry Scores

Multi-dimensional alignment results.

EBV GP42↔ HLA-DQβ1

97.3

S. pyogenes M5↔ Myosin HC

91.8

CMV pp65↔ U1-snRNP

84.2

Klebsiella N↔ HLA-B27

78.6

SARS-CoV-2 N↔ Ro60

63.1

VALIDATED TARGET

Drug Target Identified

Mimicry epitope detected: EBV GP42 ↔ HLA-DQβ1 — novel RA trigger candidate with clinical validation pathway open.

ImmunoScore: 97.33D structure confirmed

Analysis Tools

Cipher

Sequence alignment

Nebula

3D embeddings

Aether

ImmunoScore

Eidolon

In-vitro design

Aurora

Visualization

Nucleus

Research notebook

AI Family

Neural Omega AI

Advanced models trained for predictive mimicry analysis.

ANA

Phi

Multi-dimensional. Always.

Every analysis integrates multiple layers of evidence. No single-axis detection — every candidate is scored across sequence, structure, biochemistry, and immunological context.

Sequence

Primary sequence alignment & homology scoring

Structure

3D protein structure similarity via embeddings

Biochemical

Physicochemical property comparison

Immunological

MHC binding prediction & T-cell epitope analysis

Clinical

Real-world patient outcome correlation via MAR

Built for every stage
of the discovery pipeline

Target Identification

Discover novel mimicry candidates for therapeutic development

Drug Repurposing

Map existing therapeutics to newly identified mimicry pathways

Patient Stratification

Group patients by molecular mechanisms for precision trials

Adverse Event Prediction

Identify cross-reactivity risks before clinical exposure

Biomarker Discovery

Connect molecular signatures to real-world clinical outcomes

Vaccine Safety Assessment

Screen vaccine antigens for self-antigen mimicry potential

Common questions

BLAST finds sequence similarity. We find functional mimicry — combining sequence, 3D structure, physicochemical properties, and immunological context in a single score. It is not a replacement for BLAST; it is a different and deeper dimension of analysis.

Absolutely. Pharma partners use the suite for target identification, patient stratification, adverse event prediction, and biomarker discovery. Enterprise licences include dedicated compute, priority support, and SLA guarantees.

You own your data and any discoveries made using our infrastructure. Neural Omega provides the computational platform. Enterprise agreements include specific IP arrangements — contact our team to discuss.

Yes. The suite runs on enterprise cloud infrastructure with autoscaling. From exploratory candidate analyses to genome-wide screens across hundreds of pathogens, we scale with your compute requirements.

Mimicry candidates identified in the suite can be directly cross-referenced with real-world patient data through MAR. This lets you move from molecular hypothesis to patient-level evidence without switching platforms.

The Molecular Mimicry Suite is targeting a 2027 launch, with select enterprise partners already in closed beta. Request early access to discuss a partnership arrangement.

The epitope you're looking for exists.

Partner with the team building the most advanced autoimmune discovery platform in the world.

Request early access Are you a researcher?